JezK

Edit File: 1594141114.M959553P4028108.mocha3025.mochahost.com,S=28051,W=28642:2,S

Envelope-to: ahf-finance@jack.ngo,
 ahmad@jack.ngo,
 dr.safar@jack.ngo,
 hadi@jack.ngo,
 haseeb.shirzada@jack.ngo,
 mirzaee@jack.ngo,
 salahuddin@jack.ngo
Delivery-date: Tue, 07 Jul 2020 12:58:34 -0400
From: <pharmacy.kdz@jack.ngo>
To: <dr.safar@jack.ngo>
Cc: <ahmad@jack.ngo>,
	<mirzaee@jack.ngo>,
	<salahuddin@jack.ngo>,
	<hadi@jack.ngo>,
	"'Shirzada'" <haseeb.shirzada@jack.ngo>,
	<ahf-finance@jack.ngo>
References: <000401d6541e$44d09240$ce71b6c0$@jack.ngo>
In-Reply-To: <000401d6541e$44d09240$ce71b6c0$@jack.ngo>
Subject: RE: Ringer Serum Not Received
Date: Tue, 7 Jul 2020 09:58:36 -0700
Message-ID: <008001d6547f$dd848e40$988daac0$@jack.ngo>
MIME-Version: 1.0
Content-Type: multipart/related;
	boundary="----=_NextPart_000_0081_01D65445.312F2C20"
Thread-Index: AQIkdYwWb7gHoDdksDj0jgFFHr6Dv6hgCPqQ
Content-Language: en-us

This is a multipart message in MIME format.

------=_NextPart_000_0081_01D65445.312F2C20
Content-Type: multipart/alternative;
	boundary="----=_NextPart_001_0082_01D65445.312F2C20"

------=_NextPart_001_0082_01D65445.312F2C20
Content-Type: text/plain;
	charset="UTF-8"
Content-Transfer-Encoding: quoted-printable

Dear Dr. sahib Safar,

=20

First of all I am sorry for late response because nowadays we are busy =
with packing and supply, as we had a phone communication regarding this =
issue, again I want to let you know that, most of IV-Infusions are short =
at the market including (Ringer Lactate 1000ml) and this is a big =
challenge for Trauma and BPHS projects, as KBL pharmacy team working =
closely with suppliers to solve this issue ASAP, they informed me that =
in the next future we will receive IV-Infusions from suppliers, also =
please review the following points and if there be any comment please =
let me know.

1.        we supplied to type of ringer for each FATP clinics, (Ringer =
500ml with complete Qty as it was on the distribution list and 20 bag of =
Ringer 1000ml for each FHA clinics because we didn=E2=80=99t receive it =
completely from supplier due to shortage of this item at the market.

2.       As it=E2=80=99s an emergency project please let the HFs staff =
under coverage of trauma project should know that anytime they face with =
shortage of pharmaceutical items they can request immediately, =
it=E2=80=99s better that they should have a logical prediction of =
medicine usage and request before they face stock out of medicine, as I =
oriented them at pharmacy section, aslo if you persist it again it will =
be great.

3.       When I done with pharmaceutical supply I will work on =
pharmaceutical request of trauma project for next quarter because we =
should not have delay on pharmaceutical supply.

Also anytime you need my help please let me know.

=20

From: dr.safar@jack.ngo [mailto:dr.safar@jack.ngo]=20
Sent: Monday, July 6, 2020 10:20 PM
To: pharmacy.kdz@jack.ngo
Cc: ahmad@jack.ngo; mirzaee@jack.ngo; salahuddin@jack.ngo; =
hadi@jack.ngo; 'Shirzada' <haseeb.shirzada@jack.ngo>; =
ahf-finance@jack.ngo
Subject: Ringer Serum Not Received

=20

Dear Dr Sahib Jamal

=20

First of all I would like to appreciate your tireless efforts towards =
AHF project, your efforts made our job easy. Secondly Ringer (1000ml) =
serum is still not received for FATPs, since the project is emergency =
and this Medicine is needed for each traumatic patients, it will be =
better we provide them ASAP. Please update us on this regard so we can =
provide information to our stakeholders as well.=20

=20

Thank you & Best Regards,,,

=20

Dr-Mohammad Hashim =E2=80=9CSafar=E2=80=9D MD/GP/Social Service Provider

Project Manager-AHF Project

Just for Afghan Capacity and Knowledge       =D8=A8=D9=84=D9=86=D8=AF =
=D8=A8=D8=B1=D8=AF=D9=86 =D8=B3=D8=B7=D8=AD =D8=AF=D8=A7=D9=86=D8=B4 =
=D9=88 =D8=AA=D9=88=D8=A7=D9=86=D9=85=D9=86=D8=AF=DB=8C =
=D8=A7=D9=81=D8=BA=D8=A7=D9=86=D9=87=D8=A7 (=D8=AC=DA=A9) =20

Address: Kunduz,Kocha Sinama,First Region

Beside Da Afghanistan Bank, House # 08

Ph: +93 787 047 554 - +93 744 990 143 - +93792711163

Email: <mailto:Dr.Safar@jack.ngo> Dr.Safar@jack.ngo

Email: <mailto:Parvez.Safar@gmail.com> Parvez.Safar@gmail.com=20

Website:www.jack.ngo

=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D

This e-mail and any files transmitted with it may contain privileged or =
confidential information. It is solely for use by the individual for =
whom it is intended, even if addressed incorrectly. If you received this =
e-mail in error, please notify the sender; do not disclose copy, =
distribute, or take any action in reliance on the contents of this =
information; and delete it from your system. Any other use of this =
e-mail is prohibited. The views expressed herein are those of the author =
and do not necessarily reflect the views or policies of jack =
(Afghanistan). Electronic transmissions may be recorded and =
monitored.For Verification Please Read the Barcode Reader. =20

=20

------=_NextPart_001_0082_01D65445.312F2C20
Content-Type: text/html;
	charset="UTF-8"
Content-Transfer-Encoding: quoted-printable

<html xmlns:v=3D"urn:schemas-microsoft-com:vml" =
xmlns:o=3D"urn:schemas-microsoft-com:office:office" =
xmlns:w=3D"urn:schemas-microsoft-com:office:word" =
xmlns:m=3D"http://schemas.microsoft.com/office/2004/12/omml" =
xmlns=3D"http://www.w3.org/TR/REC-html40"><head><meta =
http-equiv=3DContent-Type content=3D"text/html; charset=3Dutf-8"><meta =
name=3DGenerator content=3D"Microsoft Word 15 (filtered medium)"><style></style></head><body lang=3DEN-US =
link=3D"#0563C1" vlink=3D"#954F72"><div class=3DWordSection1>Dear Dr. sahib =
Safar,<o:p></o:p><o:p>&nbsp;</o:p>First of all I am sorry =
for late response because nowadays we are busy with packing and supply, =
as we had a phone communication regarding this issue, again I want to =
let you know that, most of IV-Infusions are short at the market =
including (Ringer Lactate 1000ml) and this is a big challenge for Trauma =
and BPHS projects, as KBL pharmacy team working closely with suppliers =
to solve this issue ASAP, they informed me that in the next future we =
will receive IV-Infusions from suppliers, also please review the =
following points and if there be any comment please let me =
know.<o:p></o:p><![if =
!supportLists]>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; =
<![endif]>=C2=A0we supplied to type of ringer for each =
FATP clinics, (Ringer 500ml with complete Qty as it was on the =
distribution list and 20 bag of Ringer 1000ml for each FHA clinics =
because we didn=E2=80=99t receive it completely from supplier due to =
shortage of this item at the market.<o:p></o:p><![if !supportLists]>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; =
<![endif]>As it=E2=80=99s an emergency project please let =
the HFs staff under coverage of trauma project should know that anytime =
they face with shortage of pharmaceutical items they can request =
immediately, it=E2=80=99s better that they should have a logical =
prediction of medicine usage and request before they face stock out of =
medicine, as I oriented them at pharmacy section, aslo if you persist it =
again it will be great.<o:p></o:p><![if =
!supportLists]>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; =
<![endif]>When I done with pharmaceutical supply I will =
work on pharmaceutical request of trauma project for next quarter =
because we should not have delay on pharmaceutical =
supply.<o:p></o:p>Also anytime you need my help please let me =
know.<o:p></o:p><o:p>&nbsp;</o:p><div><div =
style=3D'border:none;border-top:solid #E1E1E1 1.0pt;padding:3.0pt 0in =
0in 0in'>From: dr.safar@jack.ngo =
[mailto:dr.safar@jack.ngo] Sent: Monday, July 6, 2020 10:20 =
PM To: pharmacy.kdz@jack.ngo Cc: ahmad@jack.ngo; =
mirzaee@jack.ngo; salahuddin@jack.ngo; hadi@jack.ngo; 'Shirzada' =
&lt;haseeb.shirzada@jack.ngo&gt;; =
ahf-finance@jack.ngo Subject: Ringer Serum Not =
Received<o:p></o:p></div></div><o:p>&nbsp;</o:p>Dear Dr =
Sahib Jamal<o:p></o:p><o:p>&nbsp;</o:p>First of all I would like to appreciate your tireless =
efforts towards AHF project, your efforts made our job easy. Secondly =
Ringer (1000ml) serum is still not received for FATPs, since the project =
is emergency and this Medicine is needed for each traumatic patients, it =
will be better we provide them ASAP. Please update us on this regard so =
we can provide information to our stakeholders as well. =
<o:p></o:p><o:p>&nbsp;</o:p>Thank you &amp; Best =
Regards,,,<o:p></o:p><img width=3D61 height=3D48 =
id=3D"Picture_x0020_21" src=3D"cid:image001.jpg@01D6543F.E744FFE0" =
alt=3D"cid:image003.jpg@01D4B669.F250F440"><=
o:p></o:p>&n=
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p>Dr-Mohammad Hashim =E2=80=9CSafar=E2=80=9D =
MD/GP/Social Service =
Provider<o:p></o:p>Project Manager-AHF =
Project<o:p></o:p>Just for Afghan Capacity and =
Knowledge&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; =
&nbsp;=D8=A8=D9=84=D9=86=D8=AF =D8=A8=D8=B1=D8=AF=D9=86 =
=D8=B3=D8=B7=D8=AD =D8=AF=D8=A7=D9=86=D8=B4 =D9=88 =
=D8=AA=D9=88=D8=A7=D9=86=D9=85=D9=86=D8=AF=DB=8C =
=D8=A7=D9=81=D8=BA=D8=A7=D9=86=D9=87=D8=A7 (=D8=AC=DA=A9)&nbsp; =
<o:p></o:p>Address: Kunduz,Kocha Sinama,First =
Region<o:p></o:p>Beside Da Afghanistan Bank, House # =
08<o:p></o:p>Ph: +93 787 047 554 - +93 744 990 143 - =
+93792711163<o:p></o:p>Email: <a =
href=3D"mailto:Dr.Safar@jack.ngo">Dr.Safar@jack.ngo</a><o:p></o:p>Email: <a =
href=3D"mailto:Parvez.Safar@gmail.com">Parvez.Safar@gmail.com</a> <o:p></o:p>Website:www.jack.ngo<o:p></o:p><=
p class=3DMsoNormal>=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
<o:p></o:p>This e-mail and any files =
transmitted with it may contain privileged or confidential information. =
It is solely for use by the individual for whom it is intended, even if =
addressed incorrectly. If you received this e-mail in error, please =
notify the sender; do not disclose copy, distribute, or take any action =
in reliance on the contents of this information; and delete it from your =
system. Any other use of this e-mail is prohibited. The views expressed =
herein are those of the author and do not necessarily reflect the views =
or policies of jack (Afghanistan). Electronic transmissions may be =
recorded and monitored.For Verification Please Read =
the Barcode Reader.&nbsp; <![if !vml]><img width=3D92 height=3D92 =
src=3D"cid:image003.jpg@01D65445.2D993420" alt=3D"jack smart code" =
v:shapes=3D"Picture_x0020_2"><![endif]><o:p></o:p><o:p>&nbsp;</o:p></div></body></html>
------=_NextPart_001_0082_01D65445.312F2C20--

------=_NextPart_000_0081_01D65445.312F2C20
Content-Type: image/jpeg;
	name="image001.jpg"
Content-Transfer-Encoding: base64
Content-ID: <image001.jpg@01D6543F.E744FFE0>
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------=_NextPart_000_0081_01D65445.312F2C20
Content-Type: image/png;
	name="image002.png"
Content-Transfer-Encoding: base64
Content-ID: <image002.png@01D6543F.E744FFE0>

iVBORw0KGgoAAAANSUhEUgAAASIAAAEiAQAAAAB1xeIbAAAABGdBTUEAALGOfPtRkwAAAAlwSFlz
AAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX/tNXEAAAEMSURB
VGje7dnBDYMwDIVhSwzASKzOSAxQySWOE1pooIcYqdWfA1LCd3uynVLRL9YsKBQKhfoLJb4GlWkZ
1oOlnEyoaGUbXVw5rS9QoSpFYu/mEpMHhrpNvWSFulvlfoS6UZVc8kC46l+ojup9IufAruY2qova
LQ/s4r6K6qNsDkt52Fbn8bFLCBWgRNJJBqOdPOSYECpEpVaUwZZVHQ2oSOWVYMNYS02oHmoIFaB8
LJemlO9FtURQgcpyWTciZxMZFaGsKW0TuXUTRYUqr4mPv8BQkcqnQuOrDypClcKonQl1n7I7kKl0
L2p+7UT1V7kf5RIZtfUPCypEWS5bOM2JjOqvzhcKhUKhfl49AcZAJK+rvDc4AAAAAElFTkSuQmCC

------=_NextPart_000_0081_01D65445.312F2C20
Content-Type: image/jpeg;
	name="image003.jpg"
Content-Transfer-Encoding: base64
Content-ID: <image003.jpg@01D65445.2D993420>
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------=_NextPart_000_0081_01D65445.312F2C20--